IFP Advisors Inc raised its position in shares of TESARO, Inc. (NASDAQ:TSRO) by 6.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,471 shares of the biopharmaceutical company’s stock after buying an additional 265 shares during the period. IFP Advisors Inc’s holdings in TESARO were worth $625,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. BlackRock Inc. raised its position in TESARO by 4,504.8% in the first quarter. BlackRock Inc. now owns 3,409,657 shares of the biopharmaceutical company’s stock worth $524,643,000 after buying an additional 3,335,611 shares during the last quarter. TIAA CREF Investment Management LLC raised its position in TESARO by 167.9% in the first quarter. TIAA CREF Investment Management LLC now owns 367,519 shares of the biopharmaceutical company’s stock worth $56,550,000 after buying an additional 230,353 shares during the last quarter. Bank of New York Mellon Corp raised its position in TESARO by 35.0% in the first quarter. Bank of New York Mellon Corp now owns 675,597 shares of the biopharmaceutical company’s stock worth $103,954,000 after buying an additional 175,273 shares during the last quarter. Vanguard Group Inc. raised its position in TESARO by 3.7% in the first quarter. Vanguard Group Inc. now owns 2,916,132 shares of the biopharmaceutical company’s stock worth $448,705,000 after buying an additional 103,759 shares during the last quarter. Finally, White Square Capital LLP purchased a new position in TESARO during the first quarter worth $14,714,000.

TESARO, Inc. (NASDAQ:TSRO) opened at 111.85 on Friday. The stock has a 50 day moving average of $130.46 and a 200 day moving average of $149.15. The stock’s market cap is $6.06 billion. TESARO, Inc. has a 1-year low of $83.26 and a 1-year high of $192.94.

TESARO (NASDAQ:TSRO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by $0.30. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The business had revenue of $29.50 million during the quarter, compared to the consensus estimate of $18.61 million. During the same quarter last year, the company earned ($1.28) EPS. TESARO’s revenue for the quarter was down 17.6% on a year-over-year basis. Equities analysts anticipate that TESARO, Inc. will post ($8.45) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/12/ifp-advisors-inc-acquires-265-shares-of-tesaro-inc-nasdaqtsro.html.

A number of research firms recently weighed in on TSRO. Janney Montgomery Scott set a $139.00 price target on shares of TESARO and gave the company a “hold” rating in a research report on Saturday, June 10th. Cowen and Company set a $145.00 price target on shares of TESARO and gave the company a “hold” rating in a research report on Saturday, June 10th. Robert W. Baird reissued a “neutral” rating and set a $140.00 price target (down from $155.00) on shares of TESARO in a research report on Thursday. Morgan Stanley reissued an “overweight” rating and set a $183.00 price target on shares of TESARO in a research report on Thursday. Finally, FBR & Co dropped their price target on shares of TESARO from $200.00 to $195.00 and set a “mkt perform” rating on the stock in a research report on Monday, June 5th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. TESARO has an average rating of “Buy” and a consensus target price of $176.35.

In other TESARO news, VP Edward C. English sold 8,500 shares of the firm’s stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the sale, the vice president now owns 5,396 shares in the company, valued at approximately $748,155.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 40.50% of the stock is owned by corporate insiders.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO, Inc. (NASDAQ:TSRO).

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.